Dynamics of hepatitis C epidemic among people living with HIV in Estonia based on Estonian HIV cohort study

BMC Infectious Diseases

Karolin Toompere¹  Radko Avi²  Kerstin Kase²  Ene-Ly Jõgeda²  Pilleriin Soodla²  Heli Rajasaar²  Irja Lutsar²  Kristi Huik²  Merit Pauskar²  Kai Zilmer³ 

[1] Department of Epidemiology and Biostatistics, Institute of Family Medicine and Public Health, Faculty of Medicine, University of Tartu;Department of Microbiology, Institute of Biological and Translational Medicine, Faculty of Medicine, University of Tartu;Infectious Diseases Clinic, West-Tallinn Central Hospital;

关键词: HIV;    Hepatitis C;    Co-infection;    Intravenous drug use;    Eastern Europe;   

DOI  :  10.1186/s12879-021-06521-w

来源: DOAJ

【 摘 要 】

Abstract Background Estonia has a typical Eastern European HIV epidemic where the most frequent co-infection is chronic hepatitis C (HCV). We aimed to describe the changes in HCV prevalence, the distribution of HCV genotypes (GT), and HCV treatment in Estonian people living with HIV over 15 years. Methods We used data of subjects included to the Estonian HIV Cohort Study (E-HIV) before 31st of December 2015. We compared two time periods—first, 1st of January 2000 to 31st of December 2008 when the HIV epidemic was mostly spreading among people who inject drugs (PWID) and second, 1st of January 2009 to 31st of December 2015 when HIV started to emerge to the general population. Results Of 4422 HIV positives 3708 (84%) had information about their HCV serostatus; 2706 (61%) were HCV seropositive, of latter 1625 (60%) were HCV RNA positive, 239 (9%) had their HCV GT determined, and 141 (5%) received treatment for HCV. The dominating subtypes were 1b (42%) and 3a (37%) followed by 1a (16%), and the few cases of 2 (1.5%). HCV prevalence was 1.5 times (95% CI 1.4–1.6) higher in subjects diagnosed with HIV in first as compared to those diagnosed in second period (84% vs 56%, respectively). There were more men and the median age at HIV diagnosis was lower in HIV/HCV co-infected than in HIV mono-infected patients (70% vs 47% and 24 years vs. 30 years, respectively; both p < 0.001). Conclusion There is a decrease in HCV prevalence but it remains high among HIV positive PWID, suggesting that there is need for improvement of harm reduction programs among PWID.

【 授权许可】

Unknown